drugset / Trial / NCT00234377

Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia

NCT00234377

Phase 3 Completed 550 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to document the clinical benefit of quetiapine (Seroquel) sustained release (SR) after switching from another ongoing antipsychotic treatment, regardless of the reason for the switch. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2004-11
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg
Subject Quetiapine Small molecule 800 mg

Indications